Biogen

Traded on the St. Petersburg Stock Exchange
Biogen is an American multinational biotechnology company, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases. Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Biogen stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
Debts
Net debt
Yield
Growth potential

Biogen balance sheet

Report period2018 2019 2020 2021 2022 Q2 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Biogen cash flows

Report period2018 2019 2020 2021 2022 Q2 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Biogen multipliers

Report period2018 2019 2020 2021 2022 Q2 23 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Biogen profitability

Report period2018 2019 2020 2021 2022 Q2 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Biogen assets
Biogen cash flows

Biogen dividend policy

The company doesn't provide dividends

Biogen shares

TickerNameTypeNominal valueISINPrice
BIIB:USBiogen Inc.Common share-US09062X1037$218.1
Biogen news
08.11.2023
Biogen's GAAP net income for 9 months of 2023 was $0.913 billion, down 2.6 times from $2.412 billion in the prior year. Revenue declined 2.4% to $7.449 billion from $7.629 billion a year earlier.
25.07.2023
Biogen's GAAP net income for 6 months of 2023 was $0.981 billion, down 23.2% from $1.277 billion in the prior year. Revenue declined 3.9% to $4.919 billion compared to $5.121 billion a year earlier.
25.04.2023
Biogen's GAAP net income for 3 months of 2023 was $387.6 million, up 77.4% from $218.5 million in the previous year. Revenue decreased 2.7% to $2.463 billion from $2.532 billion a year earlier.
15.02.2023
Biogen's GAAP net income for 2022 was $2.962 billion, up 71.4% from $1.728 billion the previous year. Revenue declined 7.4% to $10.173 billion from $10.982 billion a year earlier.
General information
Company nameBiogen
Tags#biotechnology, #s&p500 index
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address225 BINNEY STREET CAMBRIDGE MA 02142 7814642000
Mailing address225 BINNEY STREET CAMBRIDGE MA 02142
Websiteinvestors.biogen.com
Information disclosurewww.sec.gov